Characteristics associated with the first BCR-ABL1 rise
| Clinical context at the time of the BCR-ABL1 rise . | No. of patients . | No. of patients with a rise . | Doubling time . | First fold rise . | Measurement interval, d . | BCR-ABL1% IS before the rise . | BCR-ABL1% IS after the rise . |
|---|---|---|---|---|---|---|---|
| Relapse directly into BC | 12 | 12 | 9.0 (6.1-17.6) | 71 (18-631) | 68 (29-84) | 0.64 (0.13-9.9) | 81 (19.6-175) |
| BCR-ABL1 mutation and CP maintained | 30 | 29 | 48 (17.3-143) | 3.6 (2.1-19) | 85 (37-305) | 0.16 (0.003-7.2) | 1.2 (0.03-64) |
| Imatinib discontinuation after ≥ 2 y of CMR | 36 | 17 | 9.0 (6.9-26.5) | 9.5 (2.2-22.1) | 33 (14-63) | 0.006* (0.001-0.03) | 0.07 (0.007-0.48) |
| Complete dose interruption | 12 | 12 | 9.4 (4.2-17.6) | 10.5 (2.5-2400) | 28 (7-93) | 0.08 (0.01-4.7) | 4.0 (0.15-48) |
| Partial dose interruption | 34† | 27 | 37‡ (11.6-104) | 7.6 (2.1-234) | 84 (36-339) | 0.21 (0.01-9.9) | 3.3 (0.05-68) |
| Clinical context at the time of the BCR-ABL1 rise . | No. of patients . | No. of patients with a rise . | Doubling time . | First fold rise . | Measurement interval, d . | BCR-ABL1% IS before the rise . | BCR-ABL1% IS after the rise . |
|---|---|---|---|---|---|---|---|
| Relapse directly into BC | 12 | 12 | 9.0 (6.1-17.6) | 71 (18-631) | 68 (29-84) | 0.64 (0.13-9.9) | 81 (19.6-175) |
| BCR-ABL1 mutation and CP maintained | 30 | 29 | 48 (17.3-143) | 3.6 (2.1-19) | 85 (37-305) | 0.16 (0.003-7.2) | 1.2 (0.03-64) |
| Imatinib discontinuation after ≥ 2 y of CMR | 36 | 17 | 9.0 (6.9-26.5) | 9.5 (2.2-22.1) | 33 (14-63) | 0.006* (0.001-0.03) | 0.07 (0.007-0.48) |
| Complete dose interruption | 12 | 12 | 9.4 (4.2-17.6) | 10.5 (2.5-2400) | 28 (7-93) | 0.08 (0.01-4.7) | 4.0 (0.15-48) |
| Partial dose interruption | 34† | 27 | 37‡ (11.6-104) | 7.6 (2.1-234) | 84 (36-339) | 0.21 (0.01-9.9) | 3.3 (0.05-68) |
Data are median (range).
The BCR-ABL1 values for these patients represent the first positive value before the rise.
The 34 patients had 43 dose interruptions. One of the 34 patients also had a complete interruption and overlaps both the complete and partial interruption groups (45 patients in total with at least 1 interruption).
A rise occurred for 31 of the 43 partial interruptions, and the median doubling time was calculated for these 31 intervals.